SMS Pharmaceuticals Q4 FY26 Results: Profit Up, Dividend Recommended, Office Shift Approved
SMS Pharmaceuticals declared audited Q4 FY26 results with an unmodified audit opinion. The company recommended a final dividend of ₹0.40 per share for FY26. The registered office will shift to Kondapur, Hyderabad, effective May 25, 2026. Cost and Internal Auditors were appointed for FY27.
The financial results, dividend recommendation, and auditor appointments are material events for the company. The office shift is a significant operational change. These factors collectively have a medium impact on stakeholders.
The company reported positive financial results and recommended a dividend, indicating a healthy financial performance and a commitment to returning value to shareholders. The appointment of auditors and approval of office shifting are routine corporate actions.
SMS Pharmaceuticals Limited announced its audited financial results for the fourth quarter and the full financial year ended March 31, 2026. The company's Board of Directors, in their meeting held on May 22, 2026, approved the standalone and consolidated financial results. The statutory auditors have issued an 'Unmodified Opinion' on these results.
The company recommended a final dividend of ₹0.40 per equity share (40%) for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM).
Furthermore, the Board approved the shifting of the company's registered office within Hyderabad. The new address will be 8th Floor, Trendset Jayabheri Connect, Kondapur, Serilingampally, Hyderabad - 500084, effective from May 25, 2026.
In terms of appointments, M/s. Annapragada & Co. were appointed as Cost Auditors for FY 2026-27, and M/s. Adusumilli & Associates were re-appointed as Internal Auditors for the same financial year.
The Board meeting commenced at 10:30 AM and concluded at approximately 01:35 PM.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.